Bilash Kuila
Punjab Technical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bilash Kuila.
ACS Medicinal Chemistry Letters | 2015
Sundeep Dugar; Frank P. Hollinger; Dinesh Mahajan; Somdutta Sen; Bilash Kuila; Reena Arora; Yogesh Pawar; Vaibhav Shinde; Mahesh Rahinj; Kamal Kishore Kapoor; Rahul Bhumkar; Santosh Rai; Rakesh Kulkarni
A new class of potent PI3Kα inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Kα enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUC of 5.2 μM at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.
RSC Advances | 2016
Bilash Kuila; Yogesh Kumar; Dinesh Mahajan; Kapil Kumar; Prabhpreet Singh; Gaurav Bhargava
An efficient protocol for chemoselective synthesis of previously unknown 1,4-benzodiazepin-2-ones and dienyl thiazolidin-4-one carboxylates in excellent yields by ring transformation reactions of functionally decorated 2-azetidin-3-thiazolidin-4-ones is reported.
Bioorganic & Medicinal Chemistry Letters | 2015
Sundeep Dugar; Frank P. Hollinger; Bilash Kuila; Reena Arora; Somdutta Sen; Dinesh Mahajan
Over activation of the PI3K/Akt/mTOR pathway is found in most cancer tumor types. Controlled regulation of this pathway using PI3K inhibitors can provide therapeutic significance in cancer treatment. Herein, we report the synthesis and evaluation of pyrrolotriazine based novel small molecules as pan-PI3K inhibitors. The SAR studies based on in vitro potency along with microsomal metabolic stability screening, identified 18 as a preclinical lead found to be suitable for in vivo evaluation. The identified lead was also found to be a selective inhibitor of PI3K isoforms and mTOR when screened across a panel of 23 homologous kinases.
RSC Advances | 2016
Bilash Kuila; Dinesh Mahajan; Prabhpreet Singh; Gaurav Bhargava
This manuscript describes a study on relatively unexplored halogen mediated 7-exo-dig/trig cyclization reactions of 2-(2-amino-aryl)-3-prop-2-ynyl/allyl-thiazolidin-4-ones for the formation of thiazole condensed 1,4-benzodiazepines in good yields. The reactions are facile, chemoselective and involve the use of simple substrates leading to synthesis of diversely functionalized 1,4-benzodiazepines. The synthesis of such condensed 1,4-benzodiazepines is important in terms of their usefulness as biological active agents.
Tetrahedron Letters | 2014
Yogesh Kumar; Bilash Kuila; Dinesh Mahajan; Prabhpreet Singh; Balaram Mohapatra; Gaurav Bhargava
Tetrahedron Letters | 2015
Bilash Kuila; Dinesh Mahajan; Prabhpreet Singh; Gaurav Bhargava
Synlett | 2015
Priyanka Sharma; Maninder Jeet Kaur Mann; Bilash Kuila; Prabhpreet Singh; Gaurav Bhargava
Synthesis | 2014
Sundeep Dugar; Amit Sharma; Bilash Kuila; Dinesh Mahajan; Sandeep Dwivedi; Vinayak Tripathi
European Journal of Organic Chemistry | 2018
Bilash Kuila; Maninderjeet Kaur; Prabhpreet Singh; Gaurav Bhargava
Synlett | 2017
Bilash Kuila; Kapil Kumar; Dinesh Mahajan; Prabhpreet Singh; Gaurav Bhargava